Single-chain urokinase-type plasminogen activator (scu-PA) possesses enzymatic activity that increases by 2-3 orders of magnitude upon binding to its cellular cofactor, the u-PA receptor (u-PAR), hence activating an enzymatic cascade initially composed of zymogens. The present study demonstrates that plasminogen activator inhibitor type 3 (PAI-3) reversibly inhibits scu-PA in solution, maintaining the system "off." Because the scu-PA/PAI-3 interaction is reversible, cellular expression of u-PAR allows partitioning of scu-PA from PAI-3 to u-PAR with resultant expression of full enzymatic activity. PAI-3 that was originally complexed to scu-PA remains in solution, retaining its functional activity. Importantly, the scu-PA on cell surface u-PAR is protected from PAI-3 inhibition, remaining an effective activator in a PAI-rich environment. Plasmin formed as a result of scu-PA activity then cleaves scu-PA to the mature protease, two-chain u-PA (tcu-PA), which is efficiently and irreversibly inhibited by PAI-3 via the standard serpin mechanism, even on u-PAR. This data generates a new hypothesis which, in contrast to the previous paradigm, holds that receptor bound scu-PA is the initiating enzyme and that tcu-PA is generated not to augment enzymatic activity but rather to allow for inhibition and therefore appropriate regulation of the process.
A number of processes involve proteolytic cascades wherein a given zymogen is proteolytically activated by the enzyme that precedes it in the cascade. An example of such a system is plasmin-dependent cell surface proteolysis, where plasmin is generated at the cell surface from its inactive precursor, plasminogen, via the proteolytic activity of urokinase type plasminogen activator (u-PA) 1 (1). There have been several conundra about the initiation of plasminogen activation. First, u-PA is synthesized and secreted as a zymogen, single-chain u-PA (scu-PA), which requires cleavage to the mature protease, two-chain u-PA (tcu-PA) to manifest full enzymatic activity in solution (2, 3) . Because tcu-PA is required to generate plasmin, and plasmin is required to generate tcu-PA, how the process is initiated has been a puzzle (4) . However, scu-PA belongs to a select subset of zymogens that demonstrate a small but measurable amount of enzymatic activity in solution (5) (6) (7) (8) . Interestingly, upon binding to the cellular u-PA receptor (u-PAR), scu-PA increases its plasminogen-activating efficiency by 2-3 orders of magnitude, while remaining in the single-chain form (6, 9) . Hence it is likely that scu-PA bound to cellular u-PAR is the initiating enzyme of the cascade. It remains unexplained why scu-PA in solution within biological fluids exerts no enzymatic activity, whereas purified scu-PA at identical concentrations activates plasminogen (3, (5) (6) (7) 10) .
Another conundrum involves regulation. The generation of plasmin by tcu-PA and the generation of tcu-PA by plasmin creates a positive feedback loop that would accelerate proteolysis once initiated. However, physiologic cell migration requires that cell surface proteolysis is restricted to the immediate area of the cell membrane and that it is down-regulated when the cell stops. Hence there must be a mechanism for damping proteolysis, something that seems inconsistent with a positive feedback loop (11) .
To address these conundra, the present study examined the role of plasminogen activator inhibitor type 3 (PAI-3, also known as the protein C inhibitor) in regulating u-PA-mediated plasminogen activation. Although we have previously shown that both PAI-1 and PAI-2 are capable of regulating plasminogen activation (12, 13) , PAI-2 is found in few biological fluids, and PAI-1 is present in concentrations that may be inadequate to explain the complete masking of scu-PA enzymatic activity (12, 14) . In contrast, PAI-3 is present in high concentrations in plasma, urine, and seminal fluid (15) . It is also the predominant serpin found complexed to tcu-PA in biological fluids (15) .
The experiments in this report demonstrate a novel reversible interaction between scu-PA (the activating protease) and PAI-3 (the regulatory serpin). Moreover, rather than the previous paradigm of cell surface plasminogen activation, the data suggest a hypothesis with receptor bound scu-PA as the pertinent activating enzyme and with tcu-PA being generated not to augment activity but to allow the system to be inhibited.
EXPERIMENTAL PROCEDURES
Proteins and Reagents-Human scu-PA was generously supplied by Dr. Jack Henkin of Abbott Laboratories and was sequentially treated with 5 mM DFP and Glu-Gly-Arg-chloromethylketone as described previously to inactivate traces of tcu-PA that might be present (6, 12, 13) . Dr. Henkin also generously supplied the amino-terminal fragment (ATF) of u-PA, which possesses the high affinity receptor binding determinants of u-PA (16) . Glu 158 -scu-PA was prepared and treated as described previously to ensure no plasmin-cleavable form of scu-PA was present (6, 13) . PAI-3 was prepared as described previously (17) . Plasminogen-free fibrinogen was kindly supplied by Dr. Michael Mosesson, Milwaukee, WI. Plasminogen was prepared as described previously (12, 18) . Polyacrylamide, SDS, and reagents for gels were from Bio-Rad; ovalbumin was from Sigma; and other reagents were of the highest grade available.
Methods-Iodination of proteins, SDS-PAGE, the 125 I-fibrin plate assay, and the direct, plasmin-independent 125 I-plasminogen cleavage assay were carried out exactly as described previously (6, 12, 13, 19) . 125 I-tcu-PA was generated from 125 I-scu-PA by cleavage with plasminSepharose as described previously (6) . In some preparations, residual 125 I-scu-PA remains and is seen as a 55-kDa band on the autoradiograms. Variable amounts of residual 125 I-scu-PA did not influence the observed results.
U-PA/PAI-3 Interactions-Detection of SDS-stable complexes between 125 I-scu-PA and PAI-3 was performed by incubating 75 ng of 125 I-scu-PA with buffer or with 75 or 750 ng of the indicated PAI in a final volume of 30 l of TBS containing 0.01% Triton X-100 for 3 h at 37°C, followed by the addition of gel buffer containing 2-mercaptoethanol and analysis by 10% SDS-PAGE and autoradiography. Detecting competition between scu-PA and 125 I-tcu-PA for interaction with PAI-3 entailed incubating the indicated amount of scu-PA (or plasminogen as a control) with 75 ng of PAI-3 in 10 l of TBS for 30 min at 37°C. 125 I-tcu-PA (75 ng) was then added in 5 l of TBS to each reaction for the indicated time at 37°C. The reactions were analyzed by SDS-PAGE under reducing conditions and autoradiography.
Reversibility of u-PA/PAI-3 Interactions-Preliminary experiments determined conditions under which all scu-PA in a solution was complexed to PAI-3 as assessed by inhibition of 125 I-plasminogen cleavage. Scu-PA⅐PAI-3 complexes were established under such conditions (i.e. all scu-PA in complex with PAI-3), and increasing numbers of U-937 cells with unoccupied u-PAR (see below) were added for 30 min at 37°C to allow binding of scu-PA to receptor. The cells were centrifuged, washed, and either counted for radioactivity (to measure binding in experiments using 125 I-scu-PA⅐PAI-3) or placed into a 125 I-fibrin plate assay (to measure enzymatic activity in experiments using scu-PA⅐PAI-3).
Alternatively, preliminary experiments determined conditions under which all PAI-3 was complexed to scu-PA, as assessed by the inability of PAI-3 to form complexes with 125 I-tcu-PA within the time frame defined in Figs. 1 and 2 . Scu-PA⅐PAI-3 complexes were established under such conditions (i.e. all PAI-3 in complex with scu-PA), and increasing numbers of U-937 cells with unoccupied u-PAR receptors were added for 30 min at 37°C to allow binding of scu-PA to the receptors. Such receptor binding of scu-PA would leave free PAI-3 in the supernatant. The cells were centrifuged, and the supernatant was recovered and tested for free, functional PAI-3 by the addition of 125 Itcu-PA for 10 min followed by SDS-PAGE under reducing conditions and autoradiography. Under these conditions, 125 I-tcu-PA will form SDS-stable complexes with free PAI-3 but not with PAI-3 that is in complex with scu-PA (see Fig. 1 ).
U-PAR was identified as the u-PA binding entity on U-937 cells in the above experiments by preincubating cells with the indicated concentration of u-PA ATF for 30 min at 37°C, followed by washing the cells to remove unbound ATF prior to addition of scu-PA-containing solutions. Control incubations included DIP-33-kDa protease domain of u-PA, which does not contain the high affinity receptor binding determinants.
U-937 Cells-U-937 cells were grown in RPMI 1640, 10% bovine calf serum, 25 mM HEPES, pH 7.4. Prior to use, U-937 cells were washed in RPMI 1640, 2 mM EACA, 10 M cycloheximide, and were then treated exactly as described for native human monocytes (6, 13) . These cells had all detectable endogenous u-PA removed from their surface u-PAR, and they synthesized neither u-PA or PAI (6, 13) .
Inhibition of Receptor-bound u-PA-U-937 cells with unoccupied u-PAR were incubated with 5 g of the designated form of u-PA for 30 min at 37°C, washed, and then added to the designated concentration of PAI-3 for 30 min at 37°C, washed, resuspended in 0.1 ml of RPMI 1640, and added to a 125 I-fibrin plate assay.
RESULTS AND DISCUSSION
The solution phase enzymatic activity of scu-PA was inhibited in a concentration-dependent manner by PAI-3 but not by the non-inhibitory serpin, ovalbumin, (Fig. 1A) . Parallel experiments using identical conditions, but with scu-PA being the labeled protein, demonstrated that scu-PA remained in the single-chain form throughout these reactions (Fig. 1A , legend, and see Refs. 12 and 13). Also, identical results were obtained using the plasmin-insensitive mutant Glu 158 -scu-PA. Hence it was single-chain not two-chain u-PA that was inhibited by PAI-3.
The inhibition of a mature protease by a serpin-type inhibitor is marked by formation of a 1:1 complex between protease and inhibitor that initially is reversible and then progresses to an acyl-enzyme-containing complex that is stable to denaturants (20 -22) . Incubation of 125 I-scu-PA with PAI-3 under conditions that resulted in inhibition of enzymatic activity did not yield SDS-stable complexes (Fig. 1B) , implying that PAI-3 interacts with scu-PA in a manner which results in inhibition of enzymatic activity but not formation of a covalent complex.
To investigate the interaction of scu-PA with PAI-3, we determined whether scu-PA could specifically interfere with the formation of covalent complexes between 125 I-tcu-PA and PAI-3. Increasing concentrations of scu-PA were preincubated with PAI-3, followed by a constant amount of 125 I-tcu-PA being added to each reaction. The reactions were then analyzed by SDS-PAGE and autoradiography to detect SDS-stable complexes between 125 I-tcu-PA and PAI-3. As seen in Fig. 2A , scu-PA demonstrated a concentration-dependent inhibition of complex formation between 125 I-tcu-PA and PAI-3. This inhibition was specific, as plasminogen, another serine protease zymogen, did not inhibit the formation of 125 I-tcu-PA⅐PAI-3 complexes (Fig. 2A) . However, the ability of scu-PA to prevent 125 Iplasminogen (Pg) was incubated 16 h at 37°C with scu-PA, scu-PA that had been preincubated 30 min at 37°with the indicated molar ratios of PAI-3, or with ovalbumin and analyzed by SDS-PAGE under reducing conditions, followed by autoradiography. The amount of plasmin (Pn) light chain (L.C.) formed is an accurate indicator of plasminogen activation (19) . B, PAI-3 inhibits scu-PA without formation of a covalent complex. 75 ng of 125 I-scu-PA and the indicated amounts of individual PAIs were incubated as under "Experimental Procedures" for 3 h at 37°C, followed by SDS-PAGE under reducing conditions and autoradiography.
125 I-scu-PA did not form SDS-stable complexes with PAI-3 under conditions where all scu-PA enzymatic activity was inhibited. Control reactions with PAI-1 and -2 reveal the previously described reactivity of scu-PA with these molecules (12, 13) . The limited SDSstable complex formation between 125 I-scu-PA and PAI-1 serves as a positive control that demonstrates the ability of scu-PA to form such complexes with a cognate serpin under appropriate conditions and indicates that the lack of such complexes with PAI-3 is accurate.
the formation of covalent complexes between 125 I-tcu-PA and PAI-3 was reversible with time, as the longer 125 I-tcu-PA was allowed to compete with scu-PA for interaction with PAI-3, the more 125 I-tcu-PA⅐PAI-3 complexes were formed (Fig. 2B) . Hence, the active zymogen, scu-PA, interacted specifically with PAI-3 to inhibit the intrinsic activity of scu-PA without covalent bond formation and in a way that interfered with complex formation between PAI-3 and the mature protease, 125 I-tcu-PA. Moreover, this scu-PA/PAI-3 interaction appeared to be reversible.
A similar inhibitory action by the relatively high plasma concentration of PAI-3 might explain the reversible inhibition of scu-PA added to human plasma (7). In addition, similar reversible interactions between scu-PA and both PAI-1 and PAI-2 (12, 13) suggest that reversible serpin/scu-PA interactions may also explain why endogenous scu-PA in cell culture supernatants does not exhibit enzymatic activity, whereas identical concentrations of purified scu-PA are proteolytically active (3, 5, 6, 10) .
These findings imply that PAI-3 may serve to maintain scu-PA in an inactive state until a signal for cell surface plasminogen activation, u-PAR, is present. To determine whether the scu-PA⅐PAI-3 interaction is consistent with such a role, the following experiments were performed. Scu-PA⅐PAI-3 complexes were formed under conditions determined in preliminary experiments to yield all scu-PA complexed to PAI-3. Increasing numbers of U-937 cells with unoccupied u-PAR (i.e. increasing numbers of available u-PAR) were added, and the fate of scu-PA initially bound to PAI-3 was determined. As shown in Fig. 3A , 125 I-scu-PA prebound to PAI-3 was as available for binding to u-PAR as was 125 I-scu-PA that had not been precomplexed to PAI-3. SDS-PAGE and autoradiography demonstrated that 125 I-scu-PA bound to U-937 cells remained in the single-chain form and had neither been cleaved to 125 Itcu-PA nor formed SDS-stable complexes with PAI-3 (data not shown). The scu-PA that was initially complexed to PAI-3 and then bound to U-937 u-PAR retained enzymatic activity equal to that of scu-PA that had not been precomplexed with PAI-3 (Fig. 3A) . The effect of U-937 cells was indeed because of u-PAR, as preincubating U-937 cells with the ATF of u-PA, which contains the high affinity receptor binding determinants of u-PA (16), resulted in parallel concentration-dependent inhibition of 125 I-scu-PA binding, and cell surface PA activity (Fig. 3B) . The 33 kDa protease domain of u-PA, which binds poorly to the receptor, demonstrated little inhibition.
Control experiments with 125 I-PAI-3, either alone or precomplexed to scu-PA, did not demonstrate concentration-dependent binding to U-937 cells. The times required for binding and washing of the cells did not allow differentiation between scu-PA first dissociating from PAI-3 and binding to u-PAR and the initial binding of scu-PA⅐PAI-3 complexes with subsequent dissociation. Nevertheless, the outcome of these experiments demonstrated fully functional uninhibited scu-PA on cellular u-PAR.
These experiments demonstrate that scu-PA precomplexed to PAI-3 was able to bind to cellular u-PAR and yield PA activity just as efficiently as if it had not been precomplexed to PAI-3. Hence, scu-PA⅐PAI-3 complexes were reversible, yielding fully functional protease, scu-PA.
To determine whether reversal of scu-PA⅐PAI-3 complexes also yielded fully functional serpin, PAI-3, the same experimental framework was used except that the starting conditions were those determined to yield all PAI-3 complexed to scu-PA. Increasing numbers of U-937 cells with unoccupied u-PAR were added, scu-PA was allowed to bind to U-937 u-PAR, and the cells were centrifuged. If PAI-3 remained functional, it would have dissociated from scu-PA and remained in the supernatant, available to form covalent complexes with subsequently added 125 I-tcu-PA, which was the pattern seen. As demonstrated in Fig. 4A , the more U-937 cells (i.e. the more u-PAR) were added, the more functional PAI-3 was left behind in the supernatant, able to form complexes with 125 I-tcu-PA. At the highest concentration of cells tested, the PAI-3 "liberated" from complexes with scu-PA was able to form 125 I-tcu-PA⅐PAI-3 complexes of almost equal intensity to those formed between 125 I-tcu-PA and PAI-3 that had not been precomplexed to scu-PA (three experiments, 82, 93, and 98% intensity of the 125 I-tcu-PA⅐PAI-3 band by laser densitometry of autoradiograms; with 100% being the intensity of the band obtained by adding 125 I-tcu-PA to supernatants in which PAI-3 had not been precomplexed to scu-PA). Moreover, the dissociation of scu-PA⅐PAI-3 to yield functional PAI-3 required that scu-PA interact with cell surface u-PAR, as preincubation of U-937 cells with increasing concentrations of the ATF of u-PA yielded a concentration-dependent inhibition of PAI-3 available for complex formation with 125 I-tcu-PA (Fig. 4B) . Preincubation of U-937 cells with DIP-33-kDa u-PA heavy chain had no such effect.
Hence, scu-PA⅐PAI-3 complexes were reversible and yielded functional enzyme and functional inhibitor. This demonstrates a novel reversible interaction between a serpin and a serine protease that upon dissociation yields a serpin with its reactive site loop intact and fully able to subsequently form the well A, PAI-3 prebound to scu-PA retains functional activity after dissociation from scu-PA. scu-PA⅐PAI-3 complexes were formed such that all PAI-3 was complexed to scu-PA as outlined under "Experimental Procedures." Increasing numbers of U-937 cells with unoccupied receptors as indicated in the figure were added for 30 min at 37°C and centrifuged. The supernatants were recovered, and 125 Itcu-PA was added for 10 min at 37°C followed by SDS-PAGE under reducing conditions. The 125 I-tcu-PA could form complexes with PAI-3 which was now not in complex with scu-PA because of the binding of scu-PA to the U-937 cells (Fig. 3) . The more U-937 cells were added, the more scu-PA bound to U-937 cells (Fig. 3A) and the more PAI-3 was left in solution, available to bind to subsequently added 125 I-tcu-PA. B, U-937 induced dissociation of scu-PA⅐PAI-3 is u-PAR-dependent. U-937 cells (1 ϫ 10 7 ) were preincubated with increasing concentrations of u-PA ATF as in Fig. 3B and were then added to scu-PA⅐PAI-3 complexes and treated as in Fig. 4A . By preventing scu-PA from binding to U-937 receptors in a concentration-dependent manner, ATF also prevented the liberation of free PAI-3 from scu-PA⅐PAI-3 complexes, and therefore, less 125 I-tcu-PA⅐PAI-3 was detected. The identities of the bands are as in Fig. 2. described covalent complexes with a mature serine protease (20 -23) . The key may be that the "protease" that is able to form the novel reversible complex is a zymogen that has some enzymatic activity.
The scu-PA⅐PAI-3 interaction differs from the well described interaction between a serpin and a mature protease in several ways that may have important biological ramifications. First, this is a biologically reversible interaction. The reaction between a mature protease, and a serpin is chemically reversible with regard to the protease in that cleavage of the serpin P 1 -P 1 Ј bond eventually goes to completion, yielding free functional protease and cleaved nonfunctional serpin (20, 24) . However, such an interaction is biologically irreversible, as formation of the stable covalent complex results in exposure of a cryptic determinant with resultant rapid cellular internalization and degradation of the complexes (24 -27) . In contrast, the interaction described in the present report between an enzymatically active zymogen and cognate serpin is reversible in that the complex is not internalized by cells (data not shown), and dissociation of the complex yields both enzyme and inhibitor, each of which retain full functional activity.
We therefore hypothesize that a zymogen which expresses a small amount of enzymatic activity has that activity masked in solution by a reversible interaction with an inhibitor to prevent inappropriate proteolytic activity. The active zymogen would then dissociate from the serpin and bind to an appropriate cofactor (in the case of scu-PA, it would be u-PAR) to express full proteolytic activity (6, 9) .
The hypothesis also holds that the receptor-bound zymogen would not bind serpin; otherwise, the serpin liberated from the reversible protease⅐inhibitor complex would interfere with the receptor-bound zymogen which would then not express enzymatic activity. To directly test this, the indicated forms of u-PA (Fig. 5) were bound to U-937 u-PAR, then exposed to increasing concentrations of PAI-3. Following incubation to allow the potential interaction of PAI-3 with receptor bound u-PA, the cells were tested for u-PA activity. As demonstrated in Fig. 5 , neither receptor-bound scu-PA or Glu 158 -scu-PA were inhibited by PAI-3, whereas receptor-bound tcu-PA (either added directly to cells or generated in situ by binding scu-PA then treating with plasmin) was readily inhibited by PAI-3 in a concentration-dependent manner. The U-937 cell surface plasminogen-activating activity which was not PAI-3 inhibitable was because of u-PAR-bound scu-PA as demonstrated by (i) strict plasminogen dependence, (ii) inhibition by neutralizing antibodies to u-PA but not by nonimmune IgG, and (iii) prevention by pretreating U-937 cells with ATF of u-PA but not by pretreatment with the 33-kDa proteolytic domain.
These experiments could not differentiate between u-PAR⅐ scu-PA not interacting with PAI-3 and interacting in a readily reversible manner. However, the activities of receptor-bound scu-PA were virtually identical whether it had been exposed to PAI-3 or not. Therefore, if PAI-3 does interact with u-PAR⅐scu-PA, the dissociation is likely to be relatively rapid. The end result of this fleeting interaction would be expression of effective cell surface proteolytic activity even in the presence of PAI-3.
It is also worth noting that heparin did not augment scu-PA inhibition by PAI-3 (data not shown). Therefore, PAI-3 is capable of reversibly inhibiting scu-PA to maintain the system in the "off" mode in the appropriate physiologic compartment which lacks heparin-like molecules, the solution phase. In contrast, the inhibition of tcu-PA by PAI-3 is augmented by heparin (28) . Because heparin-like molecules and u-PAR are both found on cell surfaces, u-PAR-bound tcu-PA is localized for optimum inhibition by PAI-3 under physiologic conditions.
We therefore present the following hypothesis (represented in Fig. 6 ). It has been thought that the zymogen of u-PA, the initiating enzyme of this pathway, has zero activity or very close to it, and therefore by definition the enzymatic pathway is "off." However, data presented here suggests that achieving zero activity requires that the biological system exert some energy to bring the small amount of basal proenzyme activity to an unmeasurably low level. This is achieved by the reversi- ble interaction of scu-PA with a serpin, PAI-3. This novel serpin activity is distinct from the well described covalent interaction with a mature protease. When enzymatic activity is required, cells express u-PAR, allowing for partitioning of scu-PA from PAI-3 to u-PAR. Upon binding to u-PAR, scu-PA increases its plasminogen-activating efficiency by 100 -1,000-fold (6, 9) and does not interact efficiently with PAI-3; this results in efficient and targeted PA, even in a PAI-rich environment.
Next in the hypothesis is an important regulatory step that differs significantly from the currently held paradigm which states that tcu-PA is generated to yield augmented plasminogen activation, resulting in a positive feedback loop. Under physiologic conditions, there is instead a built-in negative feedback mechanism in that plasmin cleaves scu-PA to tcu-PA. We hypothesize that the more important physiological role of generating the mature protease tcu-PA is that it (tcu-PA) can be efficiently and irreversibly inhibited, even on the cell surface, as demonstrated in Fig. 5 , and as previously shown with PAI-1 and -2 (13, 27, 29) . Covalent tcu-PA⅐PAI complexes thus formed on u-PAR are rapidly internalized via an LRP-dependent mechanism (25, 26) , clearing the enzyme from the cell surface and necessitating expression of new receptors on the cell (either recycled or synthesized) for further plasminogen activation. Hence, under this hypothesis, scu-PA bound to u-PAR is the enzyme, and tcu-PA is generated to allow inhibition of the process.
In summary, the data in this report lead us to hypothesize that the effective initiating enzyme is the active zymogen (scu-PA) bound to the activating cofactor (u-PAR). The cleavage of the zymogen (scu-PA) to the mature protease (tcu-PA) serves not to mediate an increase in proteolytic activity but rather to create a species of protease that can be efficiently and irreversibly inhibited, even when bound to the initiating cofactor (u-PAR).
Therefore, in serine protease cascades, the molecularly complex serpin-type inhibitors could serve two distinct functions: (i) to effect the reversible inhibition that keeps the system off until the appropriate initiating cofactor (i.e. u-PAR) is expressed, and (ii) the biologically irreversible inhibition that limits the process once initiated. We would hypothesize that the reversible interaction with the active zymogen might be especially dependent on secondary sites of contact between serpin and protease (20, 30) . These molecular determinants may therefore have importance for regulating the initiation of proteolysis as well as facilitating its inhibition.
